Eurobio Scientific SA - Asset Resilience Ratio
Eurobio Scientific SA (ALERS) has an Asset Resilience Ratio of 10.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALERS working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Eurobio Scientific SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Eurobio Scientific SA (ALERS) total assets.
Liquid Assets Composition Over Time
This chart breaks down Eurobio Scientific SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALERS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €26.86 Million | 10.37% |
| Short-term Investments | €393.00K | 0.15% |
| Total Liquid Assets | €27.25 Million | 10.52% |
Asset Resilience Insights
- Moderate Liquidity: Eurobio Scientific SA has 10.52% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Eurobio Scientific SA Industry Peers by Asset Resilience Ratio
Compare Eurobio Scientific SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161 |
Medical Devices | 6.28% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 5.11% |
|
Beijing Succeeder Technology Inc
SHG:688338 |
Medical Devices | 28.27% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 3.90% |
|
Profound Medical Corp
TO:PRN |
Medical Devices | 67.66% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
Annual Asset Resilience Ratio for Eurobio Scientific SA (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Eurobio Scientific SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.47% | €24.36 Million ≈ $28.47 Million |
€257.17 Million ≈ $300.66 Million |
-31.23pp |
| 2023-12-31 | 40.70% | €128.76 Million ≈ $150.53 Million |
€316.33 Million ≈ $369.82 Million |
+3.06pp |
| 2022-12-31 | 37.64% | €124.38 Million ≈ $145.41 Million |
€330.42 Million ≈ $386.29 Million |
-15.82pp |
| 2021-12-31 | 53.46% | €111.85 Million ≈ $130.77 Million |
€209.22 Million ≈ $244.61 Million |
+15.15pp |
| 2020-12-31 | 38.31% | €66.01 Million ≈ $77.18 Million |
€172.30 Million ≈ $201.43 Million |
+28.16pp |
| 2019-12-31 | 10.15% | €8.22 Million ≈ $9.61 Million |
€81.01 Million ≈ $94.70 Million |
-7.19pp |
| 2018-12-31 | 17.34% | €12.12 Million ≈ $14.17 Million |
€69.90 Million ≈ $81.72 Million |
-1.02pp |
| 2017-12-31 | 18.36% | €13.14 Million ≈ $15.36 Million |
€71.57 Million ≈ $83.68 Million |
-8.91pp |
| 2016-12-31 | 27.27% | €8.70 Million ≈ $10.17 Million |
€31.89 Million ≈ $37.28 Million |
+7.39pp |
| 2015-12-31 | 19.88% | €7.10 Million ≈ $8.30 Million |
€35.71 Million ≈ $41.75 Million |
-7.64pp |
| 2014-12-31 | 27.52% | €11.14 Million ≈ $13.03 Million |
€40.50 Million ≈ $47.35 Million |
+19.90pp |
| 2013-12-31 | 7.62% | €2.55 Million ≈ $2.98 Million |
€33.41 Million ≈ $39.06 Million |
-0.55pp |
| 2012-12-31 | 8.16% | €3.14 Million ≈ $3.67 Million |
€38.49 Million ≈ $45.00 Million |
-22.12pp |
| 2011-12-31 | 30.28% | €5.33 Million ≈ $6.23 Million |
€17.60 Million ≈ $20.58 Million |
-35.12pp |
| 2010-12-31 | 65.40% | €20.45 Million ≈ $23.90 Million |
€31.26 Million ≈ $36.55 Million |
-11.60pp |
| 2009-12-31 | 77.00% | €28.14 Million ≈ $32.90 Million |
€36.55 Million ≈ $42.73 Million |
+25.39pp |
| 2008-12-31 | 51.61% | €15.40 Million ≈ $18.01 Million |
€29.85 Million ≈ $34.89 Million |
-14.74pp |
| 2007-12-31 | 66.34% | €24.94 Million ≈ $29.16 Million |
€37.59 Million ≈ $43.95 Million |
-- |
About Eurobio Scientific SA
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more